Table 1. Plan Coverage for Specialty Treatments of Psoriasis and Psoriatic Arthritis.
| Medication | Plans, %a | |||
|---|---|---|---|---|
| Covering medication | Requiring prior authorization | Offering medication with copay | Plans with quantity limits | |
| Etanercept | 97.5 | 98.8 | 2.9 | 65.2 |
| Adalimumab | 99.8 | 98.9 | 2.9 | 40.6 |
| Golimumab | 28.6 | 96.2 | 5.5 | 12.8 |
| Ustekinumab | 99.8 | 100 | 2.9 | 54.2 |
| Certolizumab pegol | 26.9 | 100 | 5.0 | 14.4 |
| Apremilast | 35.6 | 99.9 | 5.0 | 15.7 |
| Secukinumab | 61.8 | 98.4 | 3.3 | 42.1 |
| Abatacept | 43.7 | 97.6 | 4.2 | 20.8 |
| Ixekizumab | 13.0 | 90.5 | 2.5 | 49.7 |
| Brodalumab | 10.9 | 90.1 | 4.9 | 22.5 |
| Tofacitinib | 99.8 | 98.9 | 2.9 | 78.0 |
| Guselkumab | 14.9 | 91.8 | 5.1 | 1.0 |
| Tildrakizumab | 10.0 | 100 | 5.2 | 11.8 |
| Risankizumab | 70.5 | 98.3 | 2.4 | 75.4 |
a
Percentage of plans requiring prior authorization, offering medications with copay, and imposing quantity limits were calculated among plans that covered medications.